Diagnostic Accuracy of Apparent Diffusion Coefficient and 123I-Metaiodobenzylguanidine for Differentiation of Multiple System Atrophy and Parkinson's Disease

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Umemura, Atsushi ^a   Oeda, Tomoko ^a   Hayashi, Ryutaro ^a   Tomita, Satoshi ^a   Kohsaka, Masayuki ^a   Yamamoto, Kenji ^a   Sawada, Hideyuki ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; LEVODOPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PUTAMEN; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SYMPTOMATOLOGY;

3-IODOBENZYLGUANIDINE; AGED; DIAGNOSIS, DIFFERENTIAL; DIFFUSION; FEMALE; HUMANS; MALE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PUTAMEN;

PARKINSONIA;

EID: 84876270915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061066     Document Type: Article

References (34)

1. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ, (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt4): 861-870.
2. Tolosa E, Wenning G, Poewe W, (2006) The diagnosis of Parkinson's disease. Lancet Neurol 5: 75-86.
3. Konagaya M, Sakai M, Matsuoka Y, Goto Y, Yoshida M, et al. (1999) Pathological correlate of the slitlike changes on MRI at the putaminal margin in multiple system atrophy. J Neurol 246: 142-143.
4. Konagaya M, Konagaya Y, Iida M, (1994) Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 57: 1528-1531.
5. Schrag A, Kingsley D, Phatouros C, Mathias CJ, Lees AJ, et al. (1998) Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 65: 65-71.
6. Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, et al. (1999) The combination of hypointense and hyperintense signal changes on T2-eeighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 56: 225-228.
7. von Lewinski F, Werner C, Jörn T, Mohr A, Sixel-Döring F, et al. (2007) T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians. J Neurol 254: 1184-1188.
8. Watanabe H, Saito Y, Terano S, Ando T, Kachi T, et al. (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125: 1070-1083.
9. Le Bihan D, Turner R, Douek P, Patronas N, (1992) Diffusion MR imaging: clinical applications. Am J Roentgenol 159: 591-599.
10. Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, et al. (2002) Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 58: 575-580.
11. Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, Mair KJ, Esterhammer R, et al. (2006) Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord 21: 847-852.
12. Ito M, Watanabe H, Kawai Y, Atsuta N, Tanaka F, et al. (2007) Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 78: 722-728.
13. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H, (1999) (123)I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67: 189-194.
14. Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, et al. (2000) Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 284: 44-45.
15. Druschky A, Hilz MJ, Plastsch G, Radespiel-Tröger M, Druschky K, et al. (2000) Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175: 3-12.
16. Mitsui J, Saito Y, Momose T, Shimizu J, Arai N, et al. (2006) Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 243: 101-104.
17. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, et al. (2002) Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73: 776-777.
18. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, et al. (1999) Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52: 1269-1271.
19. Sawada H, Oeda T, Yamamoto K, Kitagawa N, Mizuta E, et al. (2009) Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 16: 174-182.
20. Orimo S, Amino T, Ozawa E, Kojo T, Uchihara T, et al. (2004) A useful marker for differential diagnosis of Parkinson's disease-MIBG myocardial scintigraphy. Rinsho Shinkeigaku 44: 827-829 (in Japanese).
21. Kashihara K, Ohno M, Kawasa S, Okumura Y, (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 47: 1099-1101.
22. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y, (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76: 249-251.
23. Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, et al. (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220: 105-111.
24. Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, et al. (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22: 1771-1776.
25. Daniel SE, Lees AJ (1993) Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39: 165-172.
26. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670-676.
27. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, et al. (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13: 513-521.
28. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, et al. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25: 2649-2653.
29. Sawada H, Yamakawa K, Yamakado H, Hosokawa R, Ohba M, et al. (2005) Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 293: 932-934.
30. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, et al. (2007) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113: 81-86.
31. Nagayama H, Yamazaki M, Ueda M, Nishiyama Y, Hamamoto M, et al. (2008) Low myocardinal MIBG in multiple system atrophy with incidental Lewy body pathology: an autopsy case report. Mov Disord 15: 1055-1057.
32. Parkkinen L, Hartikainen P, Alafuzoff I, (2007) Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms. Clin Neuropathol 26: 276-283.
33. Fujishiro H, Ahn TB, Frigerio R, DelleDonne A, Josephs KA, et al. (2008) Glial cytoplasmic inclusions in neurologically normal elderly: prodromal multiple system atrophy? Acta Neuropathol 116: 269-275.
34. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, et al. (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17: 24-30.